MedTrace Logo

Weaning From Nasal High Flow Therapy

NCT05210881 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2022-01-27

No results posted yet for this study

Summary

Nasal high flow is widely used in critically ill patients admitted to the intensive care unit (ICU) for acute hypoxemic respiratory failure. It has been shown to improve patient comfort, increase oxygenation and reduce need for intubation in some patients. The Respiratory Oxygenation (ROX) index has been established as a simple tool to help clinicians identify those patients who will succeed and those who will fail under nasal high flow and therefore predict the need for intubation. However, when nasal high flow therapy is successful, little is known as to how and when weaning of this device should be performed and what are the predictors of a safe withdrawal of the device. The objectives of this retrospective exploratory study are to identify a cut-off value of the ROX index predictive of success of the withdrawal trial, to describe a one-year use of the withdrawal trial; to describe the ROX value closest to weaning from nasal high flow, and to identify factors associated with success or failure of the withdrawal trial from nasal high flow therapy in patients receiving nasal high flow therapy.

Conditions

  • Respiratory Distress Syndrome, Adult
  • Acute Hypoxemic Respiratory Failure
  • Acute Respiratory Distress Syndrome
  • Weaning Failure

Sponsors & Collaborators

  • Hôpital Louis Mourier

    lead OTHER

Principal Investigators

  • Jean-Damien Ricard, MD, PhD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2019-12-31
Completion
2021-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05210881 on ClinicalTrials.gov